Melbourne, Australia, 23 September 2019: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative In-Vitro Diagnostic (IVD) tests, is pleased to announce the receipt of $404,955 from the Company’s Research & Development Tax Incentive claim for the 2019 financial year. These funds will be used to pursue Sienna’s growth strategies as it continues to execute its vision to become a hub for the development and commercialisation of IVD tests for the global pathology market.
For further information please download the attached PDF:
Download this document
